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Undetermined thyroid cytology precludes any deﬁnitive distinction between malignant and benign lesions. Recently several
classiﬁcationshave been proposed to split this category into two or more cytological subcategories related to diﬀerent malignancy
riskrates.Thecurrent study wasperformed retrospectively to investigate theresults obtainedseparating“undetermined” cytologic
reports into two categories: “follicular lesion” (FL) and “atypia of undetermined signiﬁcance” (AUS). Biochemical, clinical, and
echographic features of each category were also retrospectively analyzed. Altogether, 316 undetermined ﬁne-needle aspirated
cytologies (FNACs) were reclassiﬁed as 74 FL and 242 AUS. Histological control leads to a diagnosis of carcinomas, adenomas,
and nonneoplastic lesions, respectively, in 42.2%, 20%, and 37.8% of AUS and in 8.3%, 69.4%, and 22.2% of FL. Among
biochemical, clinical, cytological, and echographic outcomes, altered thyroid autoantibodies, multiple versus single nodule, AUS
versus FL, and presence of intranodular vascular ﬂow were statistically signiﬁcant to diﬀerentiate adenoma from carcinoma and
fromnonneoplasticlesions,whereas nosigniﬁcantdiﬀerences were foundbetween carcinomasandnonneoplasticlesionsforthese
parameters.The results ofthisretrospective study showthatundetermined FNAC category can further be subclassiﬁedin AUS and
FL, the former showing higher malignancy rate. Further prospective studies are needed to conﬁrm our results.
1.Introduction
Fine-needle aspiration cytology (FNAC) has become the
dominant method in the evaluation of thyroid nodules,
being fast, reliable, safe, minimally invasive, cost-eﬀective,
and reaching high sensitivity and speciﬁcity [1].
FNAC has allowed a dramatic decrease in surgical treat-
ment of patients with thyroid nodular disease [2], enhancing
the percentage of malignant operated nodules over 50% [3].
However, even in adequate cellular specimens, the
method shows certain limitations and leads to an “unde-
termined” result in 4–15% of all cases [4, 5], precluding
any deﬁnitive distinction between malignant and benign
lesions.
To assess terminology, description, and interpretation of
cytological appearances and transmit them to the clinicians
in a clear and reproducible way, several classiﬁcations for
thyroid cytology report have been proposed [6–10].2 Journal of Thyroid Research
All are based on a risk of malignancy scale for adequate
specimens.“Undetermined” results are mostly composed of
atypia of undetermined signiﬁcance (AUS) and follicular
patterned lesions (FL).
According to the recent Bethesda System for Reporting
Thyroid Cytopathology (BSRTC), “atypia of undetermined
signiﬁcance/follicular lesion of undetermined signiﬁcance”
(AUS/FLUS) is a heterogeneous category that includes cases
withambiguouscytologicalﬁndings thatappeartobegreater
than what would be expected of a nonneoplastic process, yet
thedegree ofcellular or architectural atypiais insuﬃcient for
an interpretation of “follicular neoplasm” or “suspicious for
malignancy” [8].
Therefore, undetermined cytology is a sort of “grey
zone” also for the clinicians, whose main goal is a correct
therapeuticapproach to thyroid lesions, that is, surgery, with
its extension, or medical followup. Practically, most of these
lesions are surgically removed, in total or subtotal thyroidec-
tomy, although only a minority of them are malignant.
However, true malignancy incidence in undetermined
lesions is not deﬁnitely known, because not all of them
are histologically checked, and the literature reports largely
heterogeneous data.
In AUS, malignancy is reported in 25% of operated
patients, but it is thought to be closer to 5–10% of the total
[8]. Papillary carcinoma is by far the commonest tumour [3,
11, 12].
Malignancy incidence in FL is even more variously re-
ported than in AUS.
CancerratioinallFLlesions(operatedandnonoperated)
is about 20% in several surveys [3, 11–13], but other authors
reported much lesser incidences of 0–7% [14–16].
In this study we have retrospectively split “undeter-
mined” thyroid FNAC into two categories: “follicular lesion”
(FL) and “atypia of undetermined signiﬁcance” (AUS) in
order to evaluate
(i) the relative incidences of AUS and FL in thyroid FNA
specimens in our district,
(ii) the incidence of malignant lesions in AUS and FL,
(iii) the presence of biochemical, clinical, and echo-
graphic features possibly predictive of malignancy
r e l a t e dt oA U Sa n dF L .
2.Materialsand Methods
We reviewed the thyroid FNAC data of our institution from
June 2004 to December 2007.
For each FNAC, a speciﬁc module was performed, in-
cluding patient data, clinical and biochemical thyroid status
(h ypo-,h yper ,oreuth yr oidism),th yr oidaut oantibodies,and
thyroid medication. Moreover, detailed ultrasound features
such as size, echogenicity, microcalciﬁcations, boundaries,
and color Doppler vascular ﬂow pattern (intra/perinodular)
were described for each nodule.
FNACs were mainly performed by four radiologists and
one endocrinologist with ultrasound guide, using 25 or 27
gauge needles.
Two-three samplings were performed for each nodule.
Papanicolaou and May-Gr¨ unwald-Giemsa stains were both
used for FNA smears preparations.
2.1.CytologicalClassiﬁcation Criteria. Cytologicalspecimens
were evaluated by 3 pathologists, and careful cytological
description was reported for each case.
Original cytologic reports were reclassiﬁed into 5 cate-
gories: inadequate, benign, undetermined, suspicious, and
malignant, not knowing the followup.
The undetermined results were divided into two further
categories.
(1) FL for samples suggesting follicular neoplasms.
In this category were included FNACs with high
to moderate cellularity, predominantly or partially
microfollicular pattern, scanty or absent colloid, and
mild or absent nuclear atypia. Samples consisting
almost exclusively/exclusively of Hurthle cells were
also included here.
FollicularpatternedlesionsorHurthlecellslesionswithovert
cytological architectural or nuclear atypical features (that is
irregular or variably sized follicle, crowding of cells, many
single cells, pleomorphic, enlarged nuclei, nuclear grooves,
coarse and irregular chromatin, prominent and multiple
nucleoli, atypical or numerous mitosis) [17] were reported
as suspicious and were not included in this study.
(2) AUS for samples exhibiting cytological atypia or
other features raising the possibility of neoplasia, but
which were insuﬃcient to enable conﬁdent placing
into any other category.
This is intended as a broad category encompassing focal fea-
tures suggestive of papillary carcinoma, cellular atypia hin-
dered by sample preparation artifact, cellular atypia engen-
dered by cystic alteration, repair, and therapy. Atypical
lymphoid inﬁltrate was included [8, 10].
2.2. Histological, Cytological, and Clinical Followup. Corre-
sponding histologic and clinical-cytological followup was
reviewed.
The histological diagnosis was made according to the
World Health Organization guidelines [18].
The patients who did not undergo thyroid surgery,
with benign repeated FNAC, were followed by clinical and
periodic thyroid sonographic evaluation, at least once within
2 years from the last FNA. If the thyroid nodule did not
undergo any modiﬁcations it was considered “bona ﬁde”
benign.
2.3. Statistical Analysis. The descriptive analyses included
the observed frequencies calculation with the respective
percentages for each categorical variable, while median and
range were computed for patients’ age and diameter of
nodules (continuous variables).
Multivariate stepwise logistic regression analysis was
performed in order to identify clinical, echographic, andJournal of Thyroid Research 3
cytological categories associated with the lesion type (car-
cinomas versus adenomas, carcinomas versus nonneoplastic
lesions, adenomas versus nonneoplastic lesions). In stepwise
selection analysis, any signiﬁcant variables (P value ≤ .05)
are inserted in the model as covariates, but an attempt is
made to remove any insigniﬁcant variables from the model
before adding a new signiﬁcant variable to the model. Each
addition or deletion of a variable to or from a model is listed
as a separate step and at each step, a new model is ﬁtted. In
this study only the ﬁnal model is presented. Results are given
in terms of odds ratio (OR).
Multivariate analyses were performed with SAS software,
version 9.1.3 (SAS Institute Inc., SAS 9.1.3, Cary, NC, USA,
2003).
3.Results
Between June 2004 and December 2007, 2422 FNAs were
performed in 1883 patients with thyroid nodule(s). There
were 348 men and 1535 women, aged 13–88 years (median
54 years).
Reclassiﬁcation of the cytological reports yielded 397
(16.4%) nondiagnostic samples, 1554 (64.2%) benign cytol-
ogy, 84 (3.5%) diagnoses of suspect malignant neoplasia,
71 (2.9%) diagnoses of malignant cytology, and 316 (13%)
undetermined cytologic reports. 74 (3%) reports corre-
sponding to follicular lesion were reclassiﬁed as FL, and 242
(10%) reports were reclassiﬁed as AUS (Figure 1).
3.1. Histological Followup. The histological diagnosis was
available for 81 nodules of the undetermined category: 36 of
74 (48.6%) nodules classiﬁed as FL, and 45 of 242 (18.6%)
nodules classiﬁed as AUS.
There were 22malignant tumors, 34follicularadenomas,
and 25 nonneoplastic lesions.
Among malignant tumors, 19 were PTC, 15 classic and 4
follicular variant, and 3 were follicular carcinomas.
Follicular adenomas were Hurtle cells type in 13 cases
and follicular in 21 cases.
Nonneoplastic lesions have been shown to be nodular
hyperplasia in 18 cases, Hashimoto’s thyroiditis in 5, gran-
ulomatous thyroiditis in 1, and spindled, probably reactive,
lesion in 1. Among histologically proven carcinomas, 19
(42.2%) were observed in nodules with preoperative AUS
reclassiﬁcation, whereas 3 (8.3%) were observed in nodules
with preoperative FL reclassiﬁcation.
Adenomas were observed in 25 (69.4%) nodules classi-
ﬁed as FL and in 9 (20%) classiﬁed as AUS.
Seventeen benign lesions (nodular hyperplasia and thy-
roiditis) corresponded to cytological reclassiﬁcation of AUS
(37.8%) and 8 to FL (22.2%) (Table 1).
3.2.Clinical Followup. RepetitionofFNACwasperformed in
73AUSlesions. Nineresultedinadequate,46benign,10AUS,
1F L ,5s u s p i c i o u s ,a n d2m a l i g n a n t .
RepetitionofFNACwas performed in8 FL.In5cases the
same cytological category was conﬁrmed, whereas in 3 cases
the cytological diagnosis was benign.
1600
1400
1200
1000
800
600
400
200
0
I B FL AUS S M
16.4%
64.2%
3%
10%
3.5% 2.9%
Figure 1: I: inadequate; B:benign; FL: follicular lesion;AUS: atypia
ofundeterminedsigniﬁcance;S:suspiciousformalignantneoplasia;
M: malignant neoplasia. Distribution of cytological categories after
reclassiﬁcation.
For 49 lesions with repeated benign FNA (46 AUS and 3
FL), in which the patients did not undergo thyroid surgery,
clinical and echographic followup supported the benign
nature of the lesion.
3.3. Clinical and Echographic Features. Clinical, echographic
features and cytological diagnosis of histologically proven
carcinomas and adenomas and of nonneoplastic lesions with
histological or clinical followup are reported in Table 2.
No signiﬁcant statistical diﬀerences were found accord-
ing toage,gender,and thyroidfunctionbetweencarcinomas,
adenomas, and nonneoplastic lesions. Moreover, there were
no signiﬁcant diﬀerences for clinical, echographic, and
cytological reclassiﬁcation between carcinomas and nonneo-
plastic lesions. However, altered autoantibodies, multiple
nodules versus single nodule, and AUS versus FL cytological
category showed a statistically signiﬁcant diﬀerence between
carcinomas and adenomas (Table 3). In detail, after condi-
tioning on the other variables entered in the model, the
probabilityofobserving acarcinoma was morethan 15times
higherwhenthyroidautoantibodieswerealtered(OR=15.43
with a P value = .046), multiple nodules increased the
probability of identifying a carcinoma by almost 79 times
(OR = 78.94 with a P value = .003), and the presence
of AUS cytological category increased the probability of
recognizing a carcinoma by more than 21 times (OR =
21.49 with a P value = .023). Total variance explained by
these three variables entered in the ﬁnal model is 56% (R2 =
0.56) and concordance percentage is 92.9% which means
that 93 of every 100 nodules will be well classiﬁed using
alterationinthyroidautoantibodies,multiple/singlenodules,
and cytological category as predictors.
Concerning the comparison between nonneoplastic
lesions and adenomas, single nodule (versus multiple nod-
ules), follicular lesion (versus AUS), higher diameter, and
no vascular ﬂow are all statistically signiﬁcant features
in adenomas compared to nonneoplastic lesions (Table 4).
Keeping the other variables constant in the model, the4 Journal of Thyroid Research
Table 1: Histologic followup of cases.
AUS (242 cases) FL (74 cases)
45 18.6% 36 48.6%
Benign 26 57.8% 33 91.6%
Follicular adenoma 5 19.2% 16 48.5%
Hurtle cell adenoma 4 15.4% 9 27.3%
Nodular hyperplasia 11 43.3% 7 21.2%
Hashimoto thyroiditis 4 15.4% 1 3%
De Quervain thyroiditis 1 3.8% — —
Reactive nodule 1 3.8% — —
Malignant 19 42.2% 3 8,4%
Papillary carcinoma classictype 14 73.7% 1 33.3%
Follicular variant of papillary carcinoma 3 15.8% 1 33.3%
Follicular carcinoma 2 10.5% 1 33.3%
AUS: atypia of undetermined signiﬁcance; FL: follicular lesion.
Table 2: Clinical, biochemical, and echographic features of 130 thyroid nodules with histological (81 cases) or benign repeated cytology
with clinical-echographic followup (49 cases).
Carcinoma Adenoma Nodular hyperplasia/thyroiditis
22 16.9% 33 25.4% 75 57.7%
Clinical and biochemical features
Age (years)
Range 25–75 Range 18–81 Range 27–72
Median 53 Median 49 Median 51
Female 18 80.8% 26 78.8% 68 90.7%
Male 4 19.2% 7 21.2% 7 9.3%
AbHTG and/or AbTPO 7 31.8% 4 12.1% 27 36.0%
Hypothyroidism 1 4.5% — — 3 4.0%
Hyperthyroidism 1 4.5% 1 3.0% 2 2.7%
Single nodule 8 36.4% 25 75.8% 24 32.0%
Unknown — 1 3.0% 3 4.0%
Diameter (mm)
Range 6–48 Range 7–54 Range 8–50
Median 18 Median 23 Median 15
Palpable 14 63.6% 22 66.7% 35 46.7%
Echographic features
Solid 20 90.9% 26 78.8% 54 72.0%
Hypoechoic 14 70.0% 20 76.9% 37 68.5%
Hyperechoic 2 10% 1 3.8% 10 18.5%
Isoechoic 4 20% 5 19.2% 7 13.0%
Microcalciﬁcations 5 25% 5 19.2% 3 5.6%
Vascular ﬂow 4 20% 14 53.8 11 20.4%
Irregular margins 3 15% 2 7.7% 3 5.6%
Unknown — 2 6.1% 3 4.0%
Mixed 2 9.1% 5 15.1% 16 21.3%
Cystic ———— 2 2 . 7 %
Cytologic category
AUS 19 86.4% 9 27.3% 65 86.7%
FL 3 13.6% 24 72.7% 10 13.3%
AUS: atypia of undetermined signiﬁcance; FL: follicular lesion.Journal of Thyroid Research 5
Table 3: Multivariate logistic analysis of the probability of identifying a carcinoma versus an adenoma by clinical, echographic features and
cytologic category.
Parameters entered in the model OR P value Concordance percentage R2
All nodules (n = 54)
Ab altered (yes versus no) 15.43 .046
92.9% 0.56 Multiple versus single nodule 78.94 .003
Cytologic Category (AUS versus FL) 21.49 .023
Only solid nodules (n = 45) Multiple versus single nodule 29.53 .005 85.9% 0.48
Cytologic Category (AUS versus FL) 12.50 .044
AUS: atypia of undetermined signiﬁcance; FL: follicular lesion.
Table 4: Multivariate logistic analysis of the probability of identifying a benign nodule (NH and thyroiditis) versus an adenoma by clinical,
echographic features and cytologic category.
Parameters entered in the model OR P value Concordance percentage R2
All nodules (n = 108)
Multiple versus single nodule 14.47 .002
81.3% 0.38 Cytologic Category (AUS versus FL) 11.96 .000
Diameter (mm) 0.94 .043
Only solid nodules (n = 80)
Multiple versus single nodule 10.93 .006
80.8% 0.37 Cytologic Category (AUS versus FL) 8.48 .005
Vascular ﬂow (yes versus No) 0.14 .035
AUS: atypia of undetermined signiﬁcance; FL: follicular lesion.
probability of identifying a benign lesion increased by 14.5
times in case of multiple nodules (OR = 14.47 with a
P value = .002) and by 12 times with an AUS cytological
category (OR = 11.96 with a P value ≤ .0001). Finally, for
each mm. of increase in the nodule diameter, the logistic
regression model predicted a 6% decrease in the probability
of observing a nonneoplastic lesion rather than an adenoma
(OR = 0.94 and P value = .043). Concordance percentage of
the model is 81.3% and R2 is 0.38.
Taking into account only solid nodules (n = 80), the
diameter was no more statistically signiﬁcant, but another
variable entered in the model, that is, vascular ﬂow: the
presence of vascular ﬂow decreased the probability of
observing a nonneoplastic lesion by 86% (OR = 0.14 and
P value = .035).
4.Conclusions
Although FNAC has been used with success in the diagnosis
of papillary, medullary, and anaplastic thyroid carcinomas,
it is diﬃcult to assess its value in follicular lesions. The
main problem is the distinction between benign lesions,
such as follicular adenoma or nodular adenomatous goiter,
and follicular carcinoma or follicular variant of papillary
carcinoma (FVPTC).
Therefore, histological evaluation is necessary to demon-
stratecapsular/vascularinvasion forfollicularcarcinomaand
the subtle nuclear aspects in FVPTC [11].
Classiﬁcations, practically overlapping as for benign and
malignant deﬁnitions, show some substantial diﬀerences
managing undetermined lesions.
Follicularlesionsare managed intwomain diﬀerentways
depending on the classiﬁcation.
The Bethesda System distinguishes 3 subcategories: “fol-
licular neoplasm or suspicious for a follicular neoplasm”
refers to a cellular aspirate comprised of follicular cells,
most of which are arranged in an altered architectural
pattern characterized by signiﬁcant cell crowding and/or
microfollicle formation; “follicular neoplasm, Hurthle cell
type/suspicious for follicular neoplasm, Hurthle cell type”
refers to a cellular aspirate consisting exclusively (or nearly
exclusively) of Hurthle cells.
Follicular patterned aspirates that do not otherwise
fulﬁl the aforementioned criteria are set together with AUS
(AUS/FLUS).
However,a signiﬁcant diﬀerenceinmalignancyincidence
seems not to appear from the document [8].
The recently published “Guidance on the reporting of
thyroid cytology specimens” of English Royal College of
Pathologist (RCP) names “neoplasm possible” (Thy3) the
undetermined category and separates samples suggesting
follicular neoplasms (Thy3f-f for follicular) from samples
which exhibit cytological atypia or otherfeatures which raise
the possibility of neoplasia but which are insuﬃcient to
enableconﬁdentplacingintoanyothercategory(Thy3a-afor
atypia).
Operative indications emerging from BSRTC recom-
mend FNAC repetition for AUS/FLUS (with subsequent
surgery if AUS/FLUS, or worse category, are found) [8],
whereas RCP recommends an individualized and multidis-
ciplinary assessment for each patient [10].
AsforAUS,itsincidenceamong thyroidcytologicalspec-
imens is variably reported, ranging from 2% to6%, although
some heterogeneity in its deﬁnition makes itdiﬃcult to draw
consistent conclusions[3,5,11,12].The BethesdaSystemfor
Reporting Thyroid Cytopathology recommends to use this6 Journal of Thyroid Research
category as a last resort and limit its use to approximately7%
[8].
In our institution, thyroid FNAC classiﬁcation similar to
that of The Royal College of Pathologists [9, 10] has been
actuallychosen,wherethepresence/absenceofnuclearatypia
is the key of the undetermined lesions subclassiﬁcation in
AUS and FL.
In the present study, data obtained on this basis indicate
that AUS is associated with higher malignancy rates than FL.
Low malignancy incidence in FL emerging from our
study contradicts the usually accepted rates of about 20%
reported by some studies [3, 5, 13, 14, 19, 20] but it is in
agreement with others.
Two Italian studies found no cancers in all operated
nodules with cytological diagnosis of FL [15, 21].
DeMay,athistologicalexamination, found only2cancers
(none follicular) among 138 FL [16].
Such a discrepancy may reﬂect inconsistent patterns in
cytological criteria of classiﬁcation.
One of the heaviest factors inﬂuencing this discrepancy
is cellular atypia, particularly its deﬁnition and association
with follicular patterned lesions.
The role of atypia as an independent risk factor for
malignancy has been matter ofinterest and debate.Although
some authors report no correlation between atypia and
malignancy [5, 22, 23], other studies show, conversely, that
atypia alone or in association with a follicular patterned
FNAC can be linked to a higher risk of malignancy [12, 14,
16, 20, 24, 25].
Interestingly, most literature showing high malignancy
rates in FL, actually reports substantial reduction when
lesions with atypia are excluded [12, 14, 19].
Moreover, among the malignancies histologically proven
in FL, FVPTC appears to be the commonest one, whereas
follicular carcinoma and Hurthle cell carcinomas seem to be
much rarer than usually reported both in FL and, generally,
among all thyroid cancers [13–16].
It is well known that the cytological diagnosis of FVPTC
is challenging, due to a paucity or lack of well-deﬁned
nuclear features of papillary carcinoma, leading, in samples
containing few cellular groups, to a diagnosis of AUS or FL
[13].
However, an accurate evaluation of focal cytological
features and the architectural pattern has been shown to
allow a correct diagnosis of malignancy or suspect for malig-
nancy [26, 27], but adequate smears and skilled pathologists
are necessary, and this could play some role in outcome
diﬀerences.
Multivariate analysis of our data allows to draw some
other relevant conclusions.
Among the cytological undetermined lesions of thyroid,
adenomas seem to be the more correctly classiﬁable on the
basis of cytological, immunological, and ultrasound data.
Firstly, most of FL specimens lead to a histological
diagnosis of adenoma.
Secondly, thyroid autoantibodies appear to be more
common in non-neoplastic lesions and in carcinomas than
in adenomas. As for carcinomas, this is not surprising.
Coexistence of chronic lymphocytic thyroiditis and PTC has
been reported, at variable frequencies, although it remains
unclearwhetherthese twothyroiddisordersshare a common
aetiology or thyroiditis represents a host tumor immune
response [28–30].
Moreover, Kim et al. recently reported positive serum
antithyroglobulin antibodies as an independent predictor
for thyroid malignancy in thyroid nodules, regardless of the
presence of autoimmune thyroiditis [31].
Our results, although limited to thyroid cancers discov-
eredinundeterminedcytology,seemtobeinagreementwith
this observation.
Conversely, the overlapping incidences of thyroid
autoantibodies in carcinomas and in non-neoplastic lesions
in the present study could almost partially be due to the fact
that, in the latter, both autoimmune thyroiditis and nodular
hyperplasia were enclosed.
In conclusion, our outcomes suggest higher malignancy
risk in cytological undetermined thyroid lesions with atypia
than without atypia.
The very low incidence of thyroid cancer found in FL
refers to the same perplexity about an unavoidable surgical
treatment, arisen by other authors with similar results [15,
16, 21].
Although all patients with FL should be considered for
surgical resection, they should be also informed about the
low malignancy risk of their condition and other aspects,
such as underlying medical conditions and age of the
patients, presence/absence of thyroid autoantibodies, growth
rate of the nodule, which could be taken in account for the
decision.
Conversely, a more relevant indication to surgery could
be advisable for AUS.
In this lesion, FNAC repetition seems also appropri-
ate. Our data conﬁrm that about half of these aspirates are
reclassiﬁed as benign, as already reported in the literature
[3, 12].
Being based on the review of previous cytological data,
our study shares the same limitations of the retrospective
studies, not allowing a prospective, two-arm followup of
operated versus nonoperated cases. Therefore our ﬁndings
should be evaluated in this light. Anyway, we clearly doc-
umented clinical and cytological ﬁndings in subclassiﬁed
undetermined cytologiccategoryin 81noduleshistologically
checked and in 49 nodules with repeated FNAC and clinical
and echographic followup.
Two years ago our results led to the employment, in our
department, of a cytological classiﬁcation similar to that of
the RCP. A larger, prospective study design has been planned
for the risk assessment in each cytological category.
In recent years, molecular tests have been shown to
be useful in the diagnosis of thyroid neoplasms. Point
mutations in BRAF and RAS genes and gene rearrangements
involving PAX8/PPARγ and RET/PTC have been found in
approximately 70% of thyroid neoplasia [32].
The B-RAF V600E mutation has been shown as diagnos-
tic marker for PTC, and there have been many reports on its
diagnostic usefulness in reﬁning the cytological diagnosis ofJournal of Thyroid Research 7
this tumor [33–37]. But, unfortunately BRAF analysis is of
limited value in preoperative diagnosis of FVPTC [38].
Moreover, several studies indicate that molecular testing
of thyroid nodules for a panel of mutations can enhance the
accuracy of undetermined FNAC [39, 40], but at present no
single marker seems to be accurate enough to distinguish
thyroid carcinoma from its benign mimics to be introduced
in the routine [41].
Finally, our results support the indication to distinguish
undetermined thyroid cytological samples with follicular
patterned feature without atypia from the undetermined
samples with atypical cells and to relate the FNAC results
with clinical and echographic ﬁndings.
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